New drug aims to shield transplant patients from hidden virus
NCT ID NCT07368153
First seen Jan 27, 2026 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant patients who have never had EBV but receive a kidney from a donor who has. Nine participants will get either the drug or a placebo alongside standard care, and researchers will monitor side effects and viral activity for 12 weeks. The goal is to prevent EBV-related complications in this vulnerable group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel
Basel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.